Two drugs fail to prevent death, reduce hospital stays

One study presented to heart doctors showed a new drug, Otsuka Pharmaceutical Co.'s tolvaptan, improved shortness of breath and other problems in patients with severe heart failure. But that study, along with one testing Johnson & Johnson's Natrecor, failed to show that either drug helped people live longer or prevented hospital stays.

View Full Article in:

NYTimes.com · Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
European Sales Manager
SentreHEART, Inc.
Germany, Benelux, UK
REG AFFAIRS PROJ MGR - 1400000A7F
Abbott
San Jose, CA
SPECIALIST II SYSTEMS INTEGRATION - 140000033P
Abbott
Dallas, TX
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD